Detecting NASH and grading fibrosis in subjects with NAFLD using non-invasive imaging biomarkers
08:00Salem Alsaqal, Uppsala / SE
3
Changes in volumetric enhancing tumour burden on CT predicts survival outcomes in patients with neuroendocrine liver metastases after intraarterial treatments
08:00Roberto Cannella, Palermo / IT
4
Gadoxetic acid-enhanced MR imaging predictors of mortality and hepatic decompensation in Chronic Liver Disease (CLD)
08:00Lucian Beer, Vienna / AT
5
Gadoxetic acid MRI in cirrhotic patients: radiologic-pathologic correlation in nodules without arterial enhancement and hepatobiliary hypointense pattern
08:00Gianvito Candita, Pisa / IT
6
MRI extracellular volume fraction in liver fibrosis: a comparison of different blood pool measurements with MR elastography and histology
08:00Verena Obmann, Bern / CH
7
The role of liver vessel volume ratio in chronic liver disease
08:00Alexander Herold, Vienna / AT
8
Progression of portal hypertension in acute cellular rejection after liver transplantation
08:00Ji Young Choi, Seoul / KR
9
Liver MRI: assessment of liver cirrhosis severity with extracellular volume fraction